AbbVie has boosted its Alzheimer's disease pipeline with a $1.4 billion cash deal to buy Aliada Therapeutics and its anti-amyloid antibody ALIA-1758, which is in phase 1 testing. If consummated ...

Just last week, AbbVie finalized a $1.4 billion acquisition of Aliada Therapeutics, targeting an experimental Alzheimer’s treatment in early development. Brokerage firm BofA Securities ...

Rare disease specialist Chiesi Pharma has forged an alliance with US biotech Aliada Therapeutics that will apply a technology designed to get drug molecules across the blood-brain barrier (BBB).

today announced that AbbVie has closed its $1.4 billion acquisition of RA Capital's portfolio company Aliada Therapeutics. Aliada's lead investigational asset is ALIA-1758, an anti-pyroglutamate ...

Recently AbbVie closed its acquisition of Aliada Therapeutics, including a promising Alzheimer's disease candidate, for $1.4 billion in cash. And it announced that it will buy out Nimble ...

Noema Pharma appointed Michael Samar as chief Financial Officer. RyCarma Therapeutics named Adam Rosenberg, former CEO of Aliada Therapeutics and Sionna Therapeutics, as its CEO. It also hired ...

Adam Rosenberg, Chief Executive Officer, most recently served as the chief executive officer of Aliada Therapeutics and Sionna Therapeutics and brings decades of experience leading innovative ...

Among some other recent deals, the company acquired private neuroscience drugmaker biotech Aliada Therapeutics, signed a collaboration and licensing agreement with EvolveImmune Therapeutics to ...

During the fourth quarter, AbbVie completed the previously announced $1.4 billion acquisition of private biotech Aliada Therapeutics, which develops neuroscience drugs. With this new acquisition ...

For instance, in October 2024, AbbVie and Aliada Therapeutics announced a final deal whereby AbbVie will buy Aliada, a biotechnology company developing treatments for difficult central nervous ...